Publication | Open Access

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

Surgical OncologyMedicineMelanomaImmunologyImmune Checkpoint InhibitorEortc 1325-Mg/keynote-054Cancer TreatmentImmunotherapyOncologyRadiation OncologyPhase 3